SEXUAL & REPRODUCTIVE RESEARCH / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions most often asked about kisspeptin and PT-141 — based on published research, not community lore.
What is kisspeptin?
Kisspeptin is a family of endogenous neuropeptides encoded by the KISS1 gene. The precursor protein is cleaved into forms ranging from 10 to 54 amino acids, all sharing a C-terminal RF-amide motif. They bind KISS1R (GPR54), a G-protein-coupled receptor on hypothalamic GnRH neurons, triggering the pulsatile release of gonadotropin-releasing hormone (GnRH). GnRH then drives LH and FSH secretion from the pituitary, and those hormones stimulate testosterone and estrogen production in the gonads [7]. It is sometimes called metastin — the name from its original isolation — but kisspeptin is the current standard term.
What does kisspeptin do?
In human studies, kisspeptin stimulates rapid LH release across multiple populations: healthy men, healthy women and women with hypothalamic amenorrhea [1]. In women with hypothalamic amenorrhea (where the reproductive axis has shut down in response to stress, low weight or exercise), kisspeptin infusion has restored pulsatile LH secretion — roughly tripling LH pulses and sixfold-increasing pulse secretory mass compared with vehicle [4]. In an IVF context, it has triggered oocyte maturation in 95% of high-OHSS-risk patients with no hyperstimulation events [3]. In men, it dose-dependently raised LH and testosterone [5]. It acts as the upstream switch of the reproductive hormone axis, not a hormone itself.
Does kisspeptin increase testosterone?
Yes, in controlled research settings — but it does so indirectly, by stimulating the axis that makes testosterone, not by supplying it. In healthy men given IV kisspeptin-10 by continuous infusion at a higher dose (4 µg/kg/h), serum testosterone rose from 16.6 to 24.0 nmol/L [5]. This is physiologically meaningful, but it occurred under intravenous research conditions with pharmaceutical-grade peptide under medical monitoring. Whether research-grade material purchased outside a clinical setting reproduces this effect is not established. Kisspeptin is investigational and not an approved testosterone therapy.
How much does kisspeptin increase testosterone?
In the most directly relevant published human study, IV kisspeptin-10 infusion at 4 µg/kg/h raised serum testosterone from a mean of 16.6 to 24.0 nmol/L in healthy men [5] — a rise of approximately 45%. That is a research pharmacokinetic result in a specific, supervised experimental protocol. This desk never translates research doses or outcomes into recommendations; the number above is descriptive of the study, not guidance for any individual.
What is PT-141?
PT-141 is the research-chemical name for bremelanotide, a synthetic cyclic heptapeptide that activates melanocortin receptors in the brain. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge between Asp and Lys. It is an analogue of alpha-MSH developed to have central effects with reduced melanogenic (tanning) activity. As a pharmaceutical, bremelanotide is FDA-approved (NDA 210557, June 2019) as a subcutaneous injection for acquired, generalized HSDD in premenopausal women [12]. As a research chemical, it is sold for laboratory use only, outside any regulatory approval.
What is PT-141 peptide?
PT-141 is a peptide in the sense that it is a chain of amino acids — seven of them, cyclized by a lactam bridge into a ring structure. It is synthetic (not naturally occurring), and it was derived structurally from melanotan II (itself an analogue of alpha-MSH) with modifications to increase metabolic stability and shift activity toward MC4R. The "PT" prefix comes from its development code. The pharmaceutical name is bremelanotide; the research-chemical name PT-141 persists in community contexts. The two names refer to the same molecular structure [12].
What does the PT-141 peptide do?
PT-141 activates MC4R (and MC3R) in hypothalamic and limbic brain regions, engaging the neural circuits of sexual desire. In a Phase 3 trial, it produced statistically significant improvements in sexual desire scores and desire-related distress in premenopausal women with HSDD [10]. A neuroimaging study of 31 women with HSDD documented increased desire for up to 24 hours and measurable changes in brain processing of erotic stimuli — specifically enhanced amygdala-insula connectivity and altered cerebellar and supplementary-motor activity [9]. It does not act through the reproductive hormone axis, does not raise LH or testosterone, and does not act on vascular smooth muscle.
What is PT-141 used for?
In its approved pharmaceutical form (bremelanotide), it is used for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — reduced sexual desire that causes personal distress and is not attributable to another medical condition, relationship problem, or medication effect. This is the only FDA-approved indication [12]. Phase 2 erectile dysfunction data exist for men, but no Phase 3 program was completed and there is no approval for men. Research-grade PT-141 is sold for laboratory research only and is not for human therapeutic use outside the approved pharmaceutical context.
Is kisspeptin FDA-approved?
No. No kisspeptin product is approved by the FDA, EMA, or any other major regulator for any indication [2]. Twenty-nine interventional clinical trials have been completed or are ongoing, and kisspeptin has been studied in hypothalamic amenorrhea, puberty disorders, IVF, fertility, and other reproductive applications. None has progressed to an NDA or equivalent regulatory submission as of 2025. All human kisspeptin research uses pharmaceutical-grade peptide under medical supervision in research protocols — not commercially available material.
What is the difference between kisspeptin and PT-141?
They are structurally unrelated and operate on completely different parts of the reproductive/sexual system. Kisspeptin is an endogenous neuropeptide that acts upstream on the hypothalamus to drive hormone production via the GnRH-LH-FSH-testosterone/estrogen axis [7]. PT-141 is a synthetic melanocortin receptor agonist that acts on brain desire circuits without touching the hormone axis [9]. Kisspeptin is investigational and unapproved; PT-141 is FDA-approved for one specific indication in premenopausal women only. Neither approval status speaks to the other's safety or utility.
What are the main side effects of PT-141?
In the 52-week open-label extension of the Phase 3 RECONNECT trials (684 women), the most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%) and headache (12.0%) [11]. The FDA prescribing information also documents a transient increase in blood pressure and systolic and diastolic readings, and contraindicates bremelanotide in uncontrolled hypertension or known cardiovascular disease [12]. Hyperpigmentation of the face, gums and breasts has been reported with repeated frequent dosing, attributed to MC1R activation. This is what was documented in controlled trials using pharmaceutical bremelanotide; effects of unregulated research-chemical material are unknown.
Can kisspeptin help with hypothalamic amenorrhea?
It has been studied for exactly that application. In five women with hypothalamic amenorrhea, continuous IV kisspeptin-54 infusion restored pulsatile LH secretion — increasing LH pulses from 1.6 to 5.0 per 8 hours and pulse secretory mass approximately sixfold compared with vehicle [4]. The 2025 intranasal study also enrolled women with hypothalamic amenorrhea and found a +4.4 IU/L LH response matching the response in healthy women [1]. However, there are no large randomized controlled trials of kisspeptin for hypothalamic amenorrhea, no product is approved for this use, and the tachyphylaxis caution — the response attenuates with repeated exposure — applies directly to any sustained-use scenario [4].